Načítá se...
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
Background: Aromatase inhibitors (AIs) are associated with musculoskeletal pain in one third (20–47%) of breast cancer patients. Recently, CDK4/6 inhibitors have emerged as a new therapeutic approach in hormone receptor (HR)-positive breast cancer. While hematological and gastrointestinal toxicities...
Uloženo v:
| Vydáno v: | Med Sci (Basel) |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8293403/ https://ncbi.nlm.nih.gov/pubmed/34198899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medsci9020042 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|